Dr. Fred R. Hirsch on Unmet Needs in Lung Cancer

Article

Fred R. Hirsch, MD, PhD, professor of medicine, professor in pathology, University of Colorado, CEO, IASLC, discusses unmet needs in the treatment of lung cancer.

Fred R. Hirsch, MD, PhD, professor of medicine, professor in pathology, University of Colorado, CEO, International Associate for the Study of Lung Cancer (IASLC), discusses unmet needs in the treatment of lung cancer.

Recent Videos
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Image of a calendar with a thumb tack stuck on a day reading "20," and a stethoscope lying on the calendar, with an image of a clock overlaying

Opinion: Oncology Nurses Can Ease the Burden of Time Toxicity in Cancer Care

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
February 26th 2025
Article

Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Simple light blue line illustration of a lung with a tumor on a dark blue background

Zipalertinib Achieves ORR Primary Endpoint in NSCLC Study

Kyle Doherty
February 3rd 2025
Article

Zipalertinib demonstrated efficacy in pretreated NSCLC with EGFR exon 20 insertion mutations, meeting the primary endpoint of ORR in the REZILIENT1 study.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

yellow background with a white outline indicating lungs

FDA Grants Priority Review to Sunvozertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Ashling Wahner
January 10th 2025
Article

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.

yellow background with a white outline depicting lungs

Amivantamab/Lazertinib Improves Survival in EGFR+ Advanced Lung Cancer

Caroline Seymour
January 8th 2025
Article

Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.